BXCL501 + Matching Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Agitation,Psychomotor
Conditions
Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Trial Timeline
Nov 21, 2022 → Aug 15, 2025
NCT ID
NCT05658510About BXCL501 + Matching Placebo
BXCL501 + Matching Placebo is a phase 3 stage product being developed by BioXcel Therapeutics for Agitation,Psychomotor. The current trial status is completed. This product is registered under clinical trial identifier NCT05658510. Target conditions include Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05665088 | Phase 3 | Terminated |
| NCT05658510 | Phase 3 | Completed |
| NCT05271552 | Phase 3 | Completed |
Competing Products
20 competing products in Agitation,Psychomotor